Galapagos gains new antifibrotic mechanism through OncoArendi deal

Galapagos’ latest move to expand its early fibrosis pipeline, via a deal with Polish biotech OncoArendi, gives the company access to a new fibrosis-blocking immune mechanism. 

Through the exclusive collaboration and licensing agreement, Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) gains first-in-class CHIT1 inhibitor OATD-01 from OncoArendi Therapeutics S.A. in exchange for €25 million ($29 million) up front plus up to €295 million ($343 million) in development, regulatory and commercial milestones and tiered royalties up to low double-digits...